English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 62805/95882 (66%)
造訪人次 : 3961797      線上人數 : 485
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library & TKU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/78544

    題名: Clozapine Protects Bone Mineral Density in Female Patients with Schizophrenia
    作者: Lin, Chieh-hsin;Huang, Kuo-hao;Chang, Yue-cune;Huang, Yi-chen;Hsu, Wan-chih;Lin, Chun-yuan;Chou, Frank Huang-chih;Tsai, Guochuan E.;Lane, Hsien-yuan
    貢獻者: 淡江大學數學學系
    關鍵詞: Bone mineral density;clozapine;osteoporosis;prolactin;schizophrenia
    日期: 2012-08-01
    上傳時間: 2012-10-11 19:34:38 (UTC+8)
    出版者: Cambridge: Cambridge University Press
    摘要: Decreased bone mineral density (BMD) is common in patients with schizophrenia; however, the pathogenesis is unclear. Different classes of antipsychotic agents may affect BMD. This study systemically examined the effects of clozapine vs. other antipsychotics, and several hormonal and metabolic factors that may contribute to BMD in female patients with schizophrenia, who are more vulnerable than males. Forty-eight women with schizophrenia, treated with long-term antipsychotics of the prototype prolactin-sparing (PS) antipsychotic agent clozapine vs. prolactin-raising (PR) antipsychotics were enrolled. They were matched for demographic and clinical characteristics. Various factors, including blood levels of prolactin and sex hormones, psychopathological symptoms, global assessment of functioning, physical activity, and menopausal status, were determined to explore their contribution to low BMD (LBMD), defined as a dual-energy X-ray absorptiometer (DEXA) T score < -1. Overall, women receiving clozapine have better bone density than women receiving PR antipsychotics. Compared to PR antipsychotics, PS clozapine therapy is a protective factor (odds ratio 28.2, 95% confidence interval 2.37-336.10, p=0.008) for LBMD. Predictors for higher bone density in the clozapine group included higher clozapine dose (p<0.001), younger age (p<0.001), and higher thyroid-stimulating hormone level (p<0.001); in the PR group, higher body mass index (p=0.003) and lower alkaline phosphatase level (p=0.007) were associated with LBMD. This study suggests that clozapine treatment is beneficial for BMD compared to PR antipsychotic treatment in women with chronic schizophrenia, and clozapine's bone-density protecting effect is dose-related.
    關聯: The International Journal of Neuropsychopharmacology 15(7), pp.897-906
    DOI: 10.1017/S1461145711001507
    顯示於類別:[數學學系暨研究所] 期刊論文


    檔案 描述 大小格式瀏覽次數
    109. International Journal of Neuropsychopharmacology(clo BMD IJNP online2011).pdf3937KbAdobe PDF444檢視/開啟



    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library & TKU Library IR teams. Copyright ©   - 回饋